TX000045
Asset
Modulates GPCR signaling to treat pulmonary hypertension associated with heart failure with preserved ejection fraction.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Heart failure with preserved ejection fraction
Phase 2, Active not recruiting, NCT06616974, clinicaltrials.gov, Oct 31, 2026
Pulmonary hypertension
Phase 2, Active not recruiting, NCT06616974, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.